Company analysis

Regenerative Medicine Landscape

$2,995.00

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.

July 21, 2017

Company Analysis: Merck & Co

PharmaVitae explores Merck & Co’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Sumitomo Dainippon

PharmaVitae explores Sumitomo Dainippon’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Japan Pharma Outlook

Datamonitor’s Japan Pharma peer set contains the top 10 companies headquartered in Japan: Takeda Pharmaceuticals, Astellas Pharma, Daiichi Sankyo, Otsuka Pharmaceutical, Eisai, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, Dainippon Sumitomo, Shionogi & Co and Kyowa Hakko Kirin.

September 28, 2016

Trends: Hot Topic Catalyst

$750.00

The FDA Amendments Act (FDAAA) provided the FDA with new powers in relation to drug safety, including the authority to impose postmarketing requirements (PMRs) and Risk Evaluation and Mitigation Strategies (REMS) on drug manufacturers.

November 19, 2020

Celgene

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.

October 8, 2018

Company Analysis: Shionogi

PharmaVitae explores Shionogi’s prescription pharmaceutical performance and outlook through to 2029.

January 29, 2021

Company Analysis: Novo Nordisk

PharmaVitae explores Novo Nordisk’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Big Pharma Licensing Trends, 2011–15

$5,000.00

Between 2011 and 2015, Big Pharma – a peer set of approximately 16 firms across the world with large R&D and sales organizations, and sales valued at $10bn or more – signed over 1,100 drug-focused deals, growing at a compound annual growth rate of 10%.

October 14, 2016

Company Analysis: UCB

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts

2014 M&A Update

Capital allocation and M&A continue to remain levers of growth as cash reserves grow and debt remains cheap. Many companies are looking towards core-strengthening asset purchases, low-scale asset divestments, and cost-saving tax inversions.

September 28, 2016

Company Analysis: Regeneron

PharmaVitae explores Regeneron’s prescription pharmaceutical performance and outlook over 2019–29.

Acorda Company Analysis

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.

February 9, 2018

2016 M&A Outlook

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how they may influence the market and future deal-making. With short-term challenges seeing top line revenue from the PharmaVitae portfolio to grow by a modestly in 2016, transactions will aim to counter industry headwinds.

September 28, 2016

Company Analysis: Takeda

PharmaVitae explores Takeda’s prescription pharmaceutical performance and outlook over 2019–29.

January 29, 2021

Company Analysis: Astellas

PharmaVitae explores Astellas’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Company Analysis: Kyowa Kirin

PharmaVitae explores Kyowa Kirin’s prescription pharmaceutical performance and outlook over 2019–29.

January 28, 2021

Company Analysis: Boehringer Ingelheim

PharmaVitae explores Boehringer Ingelheim’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include regular earnings coverage and provide timely updates to company product forecasts.

July 21, 2020

Big Pharma Outlook 2025

$2,700.00

Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

December 20, 2016

Company Analysis: Gilead

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

Company Analysis: Vertex

PharmaVitae explores Vertex’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Incyte

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.

Company Analysis: Sanofi

PharmaVitae explores Sanofi’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.

Company Analysis: Biogen

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

2016 M&A Analysis

Datamonitor Healthcare’s PharmaVitae team explores the value in the flurry of recent deals, shedding light on incentives and how

they may influence the market and future deal-making.

September 7, 2016

CMOs in China and India: Still the Places to be?

$5,000.00

Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

November 3, 2016